A company that develops a new drug for the treatment of ocular pain associated with dry eye and other diseases of the ocular surface
Innerva Pharmaceuticals has raised €2.3M across 1 funding round from 1 investor, most recently a round in Nov 2022. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-02 | Other |
| €2.3M |
| Inveready |
| View deal → |
